)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (ARWR) investor relations material
Arrowhead Pharmaceuticals Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary5 Feb, 2026
Executive summary
Achieved first regulatory approvals for REDEMPLO in the U.S., Canada, and China for FCS, marking transition to a commercial-stage company and the first FDA-approved product.
Launched REDEMPLO in the U.S. with encouraging early prescription trends, positive payer feedback, and over 100 prescriptions received.
Advanced cardiometabolic and CNS pipelines, including new clinical programs, proprietary delivery platforms, and promising early obesity program results.
Strengthened financial position with $1.33 billion in gross proceeds from licensing, milestones, and financings, including major public offerings.
Closed major licensing deals with Sarepta and Novartis, each providing substantial upfront and milestone payments.
Financial highlights
Revenue for the quarter was $264.0 million, up from $2.5 million in the same quarter last year, primarily from licensing collaborations with Sarepta ($229.5M) and Novartis ($34.2M).
Net income attributable to shareholders was $30.8 million, or $0.22 per share, reversing a net loss of $173.1 million, or $1.39 per share, in the prior year.
Operating income was $40.8 million, compared to a loss of $161.4 million in the prior year.
Operating expenses increased to $223 million, up $59 million year-over-year, driven by higher R&D and SG&A costs.
Cash and investments totaled $917 million at quarter end, excluding additional milestone and financing proceeds received post-quarter.
Outlook and guidance
Anticipates commercial sales growth for REDEMPLO and potential launches in Canada, EU, and the U.K. in 2026.
Expects Q3 2026 readout of phase III SHASTA-3 and SHASTA-4 studies for plozasiran in SHTG, targeting a $3–4 billion opportunity.
Interim data for ARO-DimerPA and additional obesity and CNS program data expected in the second half of 2026.
Sufficient liquidity to fund operations for at least the next twelve months, supported by recent equity and convertible note offerings totaling $930 million in gross proceeds.
Eligible to receive up to $15.3 billion in additional milestone payments from partnered programs.
What drives REDEMPLO's early prescription trends?
How does new CNS delivery system differentiate ARO-MAPT?
How will new capital be deployed for pipeline?
ARO-DIMER-PA TPP for MACE benefit?
SHTG payer strategy for high-risk patients
CNS platform next steps beyond MAPT/SRP-1005?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arrowhead Pharmaceuticals earnings date
Q2 202611 May, 2026
Arrowhead Pharmaceuticals
Next Arrowhead Pharmaceuticals earnings date
Q2 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arrowhead Pharmaceuticals Inc develops therapies that leverage RNA interference (RNAi) to treat genetic diseases. Its pipeline targets conditions in areas such as liver disease, cardiovascular disease, and oncology. The company is headquartered in Pasadena, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage